Abbott Laboratories balance sheet
At the end of fiscal 2025, Abbott Laboratories had total assets of $86.71bn and shareholders' equity of $52.13bn. It held $8.52bn in cash against $12.93bn of debt: net debt of $4.41bn.
Balance sheet
| Fiscal year | 2009Dec 2009 | 2010Dec 2010 | 2011Dec 2011 | 2012Dec 2012 | 2013Dec 2013 | 2014Dec 2014 | 2015Dec 2015 | 2016Dec 2016 | 2017Dec 2017 | 2018Dec 2018 | 2019Dec 2019 | 2020Dec 2020 | 2021Dec 2021 | 2022Dec 2022 | 2023Dec 2023 | 2024Dec 2024 | 2025Dec 2025 | LTMJun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 8.8 | 3.6 | 6.8 | 10.8 | 3.5 | 4.1 | 5.0 | 18.6 | 9.4 | 3.8 | 3.9 | 6.8 | 9.8 | 9.9 | 6.9 | 7.6 | 8.5 | 5.1 |
| Receivables | 6.5 | 7.2 | 7.7 | 7.6 | 4.0 | 3.6 | 3.4 | 3.2 | 5.2 | 5.2 | 5.4 | 6.4 | 6.5 | 6.2 | 6.6 | 6.9 | 7.9 | 8.6 |
| Inventory | 3.3 | 3.2 | 3.3 | 3.8 | 2.7 | 2.6 | 2.6 | 2.4 | 3.6 | 3.8 | 4.3 | 5.0 | 5.2 | 6.2 | 6.6 | 6.2 | 6.5 | 7.3 |
| Total current assets | 23.3 | 22.3 | 23.8 | 31.3 | 19.2 | 13.6 | 14.2 | 26.8 | 20.1 | 14.6 | 15.7 | 20.4 | 24.2 | 25.2 | 22.7 | 23.7 | 26.0 | 24.5 |
| Goodwill | 13.2 | 15.9 | 15.7 | 15.8 | 9.8 | 10.1 | 9.6 | 7.7 | 24.0 | 23.3 | 23.2 | 23.7 | 23.2 | 22.8 | 23.7 | 23.1 | 24.0 | 35.2 |
| Total assets | 52.6 | 60.6 | 60.3 | 67.2 | 42.9 | 41.2 | 41.2 | 52.7 | 76.3 | 67.2 | 67.9 | 72.5 | 75.2 | 74.4 | 73.2 | 81.4 | 86.7 | 109.2 |
| Total current liabilities | 13.0 | 17.3 | 15.5 | 13.3 | 9.5 | 10.5 | 9.2 | 6.7 | 8.9 | 9.0 | 10.9 | 11.9 | 13.1 | 15.5 | 13.8 | 14.2 | 16.5 | 17.8 |
| Short-term debt | 0.2 | 2.0 | 1.0 | 0.3 | 0.0 | 0.1 | 0.0 | 0.0 | 0.5 | 0.0 | 1.3 | 0.0 | 0.8 | 2.3 | 1.1 | 1.5 | 3.0 | 3.0 |
| Long-term debt | 11.3 | 12.5 | 12.0 | 18.1 | 3.4 | 3.4 | 5.9 | 20.7 | 1.2 | 19.4 | 16.7 | 18.5 | 17.3 | 14.5 | 13.6 | 12.6 | 9.9 | 29.6 |
| Total debt | 16.5 | 18.9 | 15.4 | 20.5 | 6.6 | 7.8 | 9.0 | 22.0 | 27.9 | 19.6 | 18.1 | 18.7 | 18.1 | 16.8 | 14.7 | 14.1 | 12.9 | 32.6 |
| Shareholders' equity | 23.1 | 22.7 | 24.4 | 26.7 | 25.2 | 21.5 | 21.2 | 20.5 | 30.9 | 30.5 | 31.1 | 32.8 | 35.8 | 36.7 | 38.6 | 47.7 | 52.1 | 51.1 |
| Net debt (negative = net cash) | 7.6 | 15.3 | 8.6 | 9.7 | 3.1 | 3.8 | 4.0 | 3.4 | 18.5 | 15.7 | 14.3 | 11.9 | 8.3 | 6.9 | 7.8 | 6.5 | 4.4 | 27.5 |
| Quarter | 2024 Q3Sept 2024 | 2024 Q4Dec 2024 | 2025 Q1Mar 2025 | 2025 Q2Jun 2025 | 2025 Q3Sept 2025 | 2025 Q4Dec 2025 | 2026 Q1Mar 2026 | 2026 Q2Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Receivables | 7.1 | 6.9 | 7.3 | 8.0 | 8.1 | 7.9 | 8.2 | 8.6 |
| Inventory | 6.8 | 6.2 | 6.6 | 7.0 | 6.7 | 6.5 | 7.0 | 7.3 |
| Total current assets | 23.8 | 23.7 | 23.2 | 24.5 | 24.8 | 26.0 | 25.5 | 24.5 |
| Goodwill | 23.7 | 23.1 | 23.4 | 24.0 | 24.0 | 24.0 | 35.2 | 35.2 |
| Total assets | 74.4 | 81.4 | 81.4 | 84.0 | 84.2 | 86.7 | 110.4 | 109.2 |
| Total current liabilities | 14.9 | 14.2 | 13.0 | 13.4 | 14.6 | 16.5 | 18.4 | 17.8 |
| Short-term debt | 2.2 | 1.5 | 0.5 | 0.5 | 1.3 | 3.0 | 4.4 | 3.0 |
| Long-term debt | 12.8 | 12.6 | 12.7 | 12.9 | 11.6 | 9.9 | 29.6 | 29.6 |
| Total debt | 15.0 | 14.1 | 13.2 | 13.4 | 12.9 | 12.9 | 34.0 | 32.6 |
| Shareholders' equity | 39.8 | 47.7 | 48.8 | 50.6 | 51.0 | 52.1 | 52.1 | 51.1 |
Compare with peers
- Medtronic balance sheet
- Stryker Corporation balance sheet
- GE HealthCare balance sheet
- Boston Scientific balance sheet
- Koninklijke Philips NV balance sheet
Head to head: ABT vs MDTABT vs SYKABT vs GEHC
More: Health Care Equipment stocks compared, Health Care sector, rankings of US companies